|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Kintara Therapeutics, Inc (KTRA) |
|
|
$0.08 0.00 (0.00%) as of 4:30 Fri 11/11
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
1,680,000 |
| Market
Cap: |
141.29(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0841 - $0.0841 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kintara Therapeutics is a clinical stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. Co.'s two primary candidates are: VAL-083, a validated, DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late-stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Murphy Keith |
Director |
– • – |
2020-08-19 |
4 |
B |
$0.00 |
$0 |
D/D |
181,010 |
181,010 |
2.31 |
-4% |
|
| Bell John K |
Director |
– • – |
2020-03-31 |
4 |
A |
$0.00 |
$0 |
I/I |
29 |
9,788 |
|
- |
|
| Toth Robert Joseph Jr |
Director |
– • – |
2020-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
8 |
1,206 |
|
- |
|
| Praill Scott |
Chief Financial Officer |
• – – |
2020-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
22 |
7,452 |
|
- |
|
| Cranston Lynda Sarah |
Director |
– • – |
2020-03-31 |
4 |
D |
$0.00 |
$0 |
I/I |
(8) |
324 |
|
- |
|
| Brown Dennis M |
Chief Scientific Officer |
• – – |
2020-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
17 |
5,994 |
|
- |
|
| Bell John K |
Director |
– • – |
2019-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
29 |
9,759 |
|
- |
|
| Praill Scott |
Chief Financial Officer |
• – – |
2019-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
22 |
7,430 |
|
- |
|
| Cranston Lynda Sarah |
Director |
– • – |
2019-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
8 |
316 |
|
- |
|
| Toth Robert Joseph Jr |
Director |
– • – |
2019-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
8 |
1,198 |
|
- |
|
| Brown Dennis M |
Chief Scientific Officer |
• – – |
2019-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
17 |
5,977 |
|
- |
|
| Brown Dennis M |
Chief Scientific Officer |
• – – |
2019-12-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
7,500 |
5,960 |
|
- |
|
| Cranston Lynda Sarah |
Director |
– • – |
2019-09-30 |
4 |
A |
$0.00 |
$0 |
I/I |
8 |
308 |
|
- |
|
| Praill Scott |
Chief Financial Officer |
• – – |
2019-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
22 |
7,408 |
|
- |
|
| Brown Dennis M |
Chief Scientific Officer |
• – – |
2019-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
17 |
13,460 |
|
- |
|
| Bell John K |
Director |
– • – |
2019-09-30 |
4 |
A |
$0.00 |
$0 |
I/I |
29 |
9,730 |
|
- |
|
| Toth Robert Joseph Jr |
Director |
– • – |
2019-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8 |
1,190 |
|
- |
|
| Bell John K |
Director |
– • – |
2019-09-13 |
4/A |
B |
$0.68 |
$23,744 |
I/I |
35,000 |
35,000 |
2.1 |
- |
|
| Bell John K |
Director |
– • – |
2019-09-13 |
4 |
B |
$0.68 |
$23,744 |
D/D |
35,000 |
44,701 |
2.39 |
- |
|
| Bell John K |
Director |
– • – |
2019-06-28 |
4 |
A |
$0.00 |
$0 |
I/I |
29 |
9,701 |
|
- |
|
| Praill Scott |
Chief Financial Officer |
• – – |
2019-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
22 |
7,386 |
|
- |
|
| Toth Robert Joseph Jr |
Director |
– • – |
2019-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8 |
1,182 |
|
- |
|
| Brown Dennis M |
Chief Scientific Officer |
• – – |
2019-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
17 |
13,443 |
|
- |
|
| Cranston Lynda Sarah |
Director |
– • – |
2019-06-28 |
4 |
A |
$0.00 |
$0 |
I/I |
8 |
300 |
|
- |
|
| Praill Scott |
Chief Financial Officer |
• – – |
2019-03-29 |
4 |
A |
$0.49 |
$103 |
D/D |
211 |
73,632 |
|
- |
|
165 Records found
|
|
Page 2 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
